new paper: non-clinical interventions for preventable & treatable childhood diseases – what do we know?
new paper: by Maureen Seguin and Miguel Niño-Zarazúa
Munich Personal RePEc Archive
“What do we know about non-clinical interventions for preventable and treatable childhood diseases in developing countries?”
Preventable and treatable childhood diseases, notably acute respiratory infections and diarrhoeal diseases are the first and second leading causes of death and morbidity among young children in developing countries. The fact that a large proportion of child deaths are caused by these diseases is symptomatic of dysfunctional policy strategies and health systems in the developing world. Though clinical interventions against such diseases have been thoroughly studied, non-clinical interventions have received much less attention. This paper contributes to the existing literature on child wellbeing in two important respects: first, it presents a theory of change-based typology that emerges from a systematic review conducted on non-clinical interventions against preventable and treatable childhood diseases. Second, it pays particular attention to policies that have been tested in a developing country context, and which focus on children as the primary target population. Overall, we find that improved water supply and quality, sanitation and hygiene, as well as the provision of medical equipment that detect symptoms of childhood diseases, along with training and education for medical workers, are effective policy instruments to tackle diarrhoeal diseases and acute respiratory infections in developing countries. more…
34 page pdf
Seguin, Maureen and Niño-Zarazúa, Miguel (2013): What do we know about non-clinical interventions for preventable and treatable childhood diseases in developing countries? Published in: WIDER Working Paper Series , Vol. 2013, No. 087 (13. September 2013)
WASHLink from time to time likes to briefly note newly publish papers in hopes of giving them a wider audience – let us know if you know of paper that could use this very small piece of publicity…
The Caplow Children’s Prize is a novel humanitarian contest to save children’s lives.
A $1 million prize will be awarded to the best plan for preserving the lives of children who would otherwise die before the age of five. All prize finalists will be showcased on our website.
THE PROBLEM: 19,000 children under five die every day.
THE CONTEST: Seeks to find the best way $1 million might help.
WHO CAN APPLY: Any person or organization worldwide that:
1) works with or for children
2) could save more children’s lives with more funding
3) could save those lives within two years
4) has a great but realistic plan
HOW TO APPLY: It’s easy! Fill out a short online form by May 31st: Apply Now
- UNICEF releases recommendations on infantry mortality reduction in Georgia (en.trend.az)
- India Ink: A Conversation With: U.S.A.I.D. Administrator Rajiv Shah (india.blogs.nytimes.com)
- Child Mortality in Ethiopia (sbfphc.wordpress.com)
- Lancet: How To Save A Couple Of Million Small Children’s Lives A Year (commonhealth.wbur.org)
Web cast interview with Epidemiologist Irene Shui,
Excerpts from the story:
“A study in the Journal of the American Medical Association examines the safety and effectiveness of another rotavirus vaccine now being used.”
“Other vaccines have since taken its place. But a manufacturer’s study of one of them, the RotaTeq vaccine, suggested it, too, might cause intestinal blockage after the first dose. Epidemiologist Irene Shui, at the Harvard School Of Public Health, decided to investigate. “
““Because the rotavirus vaccine is given to almost every child in the United States, it’s crucial to monitor the vaccine’s safety,” said Shui.”
“Shui and other researchers examined the records of almost 800,000 babies who received this vaccine, including 300,000 first doses. They were looking for incidents of intussusception, the medical term for this kind of blockage. “
“We did not find an elevated risk of intussusception following any dose of the vaccine, and especially following the first dose,” she said.”